Department of Clinical Medicine
Martin Tolstrup has not added Biography.
If you are Martin Tolstrup and would like to personalize this page please email our Author Liaison for assistance.
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Jun, 2017 | Pubmed ID: 28329286
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
AIDS (London, England) Feb, 2007 | Pubmed ID: 17301572
Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America May, 2008 | Pubmed ID: 18419429
Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideia, Dako Cytomation) and recombinant antigen assay (Liaison, DiaSorin).
BMC clinical pathology Apr, 2008 | Pubmed ID: 18423001
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Feb, 2010 | Pubmed ID: 20085464
Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.
Journal of acquired immune deficiency syndromes (1999) Aug, 2011 | Pubmed ID: 21471820
Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.
PloS one , 2011 | Pubmed ID: 21731690
Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.
Virology journal Aug, 2011 | Pubmed ID: 21806819
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
BMC infectious diseases Oct, 2011 | Pubmed ID: 21970555
Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice.
Infection and immunity May, 2012 | Pubmed ID: 22371375
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
PloS one , 2012 | Pubmed ID: 22479327
Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as entry receptor.
Journal of virology Oct, 2012 | Pubmed ID: 22811542
TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.
Human vaccines & immunotherapeutics Aug, 2012 | Pubmed ID: 22854665
The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults.
PloS one , 2012 | Pubmed ID: 22860110
Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
AIDS research and human retroviruses Nov, 2012 | Pubmed ID: 22867119
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Human vaccines & immunotherapeutics May, 2013 | Pubmed ID: 23370291
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.
Human vaccines & immunotherapeutics Apr, 2013 | Pubmed ID: 23563519
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.
PloS one , 2013 | Pubmed ID: 23637967
Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models.
BMC immunology Nov, 2013 | Pubmed ID: 24245569
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
The Journal of infectious diseases Apr, 2014 | Pubmed ID: 24273179
Editorial commentary: Reversing latency in HIV-infected patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Mar, 2014 | Pubmed ID: 24336824
T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication.
PloS one , 2014 | Pubmed ID: 24404168
Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
Human vaccines & immunotherapeutics , 2014 | Pubmed ID: 24553190
Polymers fight HIV: potent (pro)drugs identified through parallel automated synthesis.
Advanced healthcare materials Jan, 2015 | Pubmed ID: 24811313
Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
Advanced healthcare materials Jan, 2015 | Pubmed ID: 25132665
Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives.
Sexual health Dec, 2014 | Pubmed ID: 25218800
Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs.
Chemical communications (Cambridge, England) Dec, 2014 | Pubmed ID: 25285337
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
AIDS (London, England) Jun, 2015 | Pubmed ID: 25870990
Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.
Molecular medicine (Cambridge, Mass.) Apr, 2015 | Pubmed ID: 25879630
High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau.
Virology journal Mar, 2015 | Pubmed ID: 25889017
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
Antimicrobial agents and chemotherapy Jul, 2015 | Pubmed ID: 25896701
Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system.
Open forum infectious diseases Jan, 2015 | Pubmed ID: 26034779
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.
PLoS pathogens Jul, 2015 | Pubmed ID: 26133551
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Journal of virology Oct, 2015 | Pubmed ID: 26223643
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
PLoS pathogens Sep, 2015 | Pubmed ID: 26379282
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
The lancet. HIV Oct, 2014 | Pubmed ID: 26423811
HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.
AIDS (London, England) Mar, 2016 | Pubmed ID: 26595541
Reversal of Latency as Part of a Cure for HIV-1.
Trends in microbiology Feb, 2016 | Pubmed ID: 26690612
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.
Mediators of inflammation , 2015 | Pubmed ID: 26696749
Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.
Advanced healthcare materials Mar, 2016 | Pubmed ID: 26789641
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.
The Journal of clinical investigation Mar, 2016 | Pubmed ID: 26854925
Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.
Journal of translational medicine Feb, 2016 | Pubmed ID: 26861779
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Journal of virology May, 2016 | Pubmed ID: 26889036
Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Vaccine Mar, 2016 | Pubmed ID: 26896686
The potential role for romidepsin as a component in early HIV-1 curative efforts.
Expert review of anti-infective therapy , 2016 | Pubmed ID: 26953620
New insights on the phenotype of HIV reservoirs.
AIDS (London, England) 06, 2016 | Pubmed ID: 27243776
Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1.
Molecular pharmaceutics 07, 2016 | Pubmed ID: 27244595
International AIDS Society global scientific strategy: towards an HIV cure 2016.
Nature medicine 08, 2016 | Pubmed ID: 27400264
Immune checkpoints and the HIV-1 reservoir: proceed with caution.
Journal of virus eradication Jul, 2016 | Pubmed ID: 27482460
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.
PLoS pathogens 08, 2016 | Pubmed ID: 27560972
Broad activation of latent HIV-1 in vivo.
Nature communications 09, 2016 | Pubmed ID: 27605062
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
The lancet. HIV 10, 2016 | Pubmed ID: 27658863
Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.
Molecular pharmaceutics 01, 2017 | Pubmed ID: 28043136
Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.
AIDS (London, England) 03, 2017 | Pubmed ID: 28272134
Beyond antiretroviral therapy: early interventions to control HIV-1 infection.
AIDS (London, England) 07, 2017 | Pubmed ID: 28463884
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Journal of virology 08, 2017 | Pubmed ID: 28539449
Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.
Chemical science Jan, 2015 | Pubmed ID: 28580095
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.
Mucosal immunology Mar, 2018 | Pubmed ID: 28766555
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.
JCI insight Aug, 2017 | Pubmed ID: 28814661
Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.
Advanced healthcare materials Dec, 2017 | Pubmed ID: 28945945
Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.
Journal of virology 01, 2018 | Pubmed ID: 29118123
Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
Human vaccines & immunotherapeutics 04, 2018 | Pubmed ID: 29172992
Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.
Journal of controlled release : official journal of the Controlled Release Society 04, 2018 | Pubmed ID: 29432822
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Lipopolysaccharide-Induced Inflammatory Responses.
mSphere Jan-Feb, 2018 | Pubmed ID: 29468194
Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.
Human vaccines & immunotherapeutics 06, 2018 | Pubmed ID: 29474139
Multiple Homozygous Variants in the STING-Encoding Gene in HIV Long-Term Nonprogressors.
Journal of immunology (Baltimore, Md. : 1950) 05, 2018 | Pubmed ID: 29632140
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.
AIDS (London, England) 08, 2018 | Pubmed ID: 29762162
HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat.
Chemical science Mar, 2016 | Pubmed ID: 29997778
Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin.
AIDS (London, England) 07, 2018 | Pubmed ID: 30001247
Whole Exome Sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules.
Scientific reports 10, 2018 | Pubmed ID: 30323326
Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
AIDS (London, England) 03, 2019 | Pubmed ID: 30531314
Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs.
Journal of controlled release : official journal of the Controlled Release Society 01, 2019 | Pubmed ID: 30552954
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.
Journal of virology 04, 2019 | Pubmed ID: 30700598
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
AIDS (London, England) 03, 2019 | Pubmed ID: 30830886
cAIMP administration in humanized mice induces a chimerization-level-dependent STING response.
Immunology 06, 2019 | Pubmed ID: 30919991
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.
AIDS (London, England) 07, 2019 | Pubmed ID: 30932955
Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) Mar, 2019 | Pubmed ID: 30937274
TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.
EBioMedicine Jul, 2019 | Pubmed ID: 31300344
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.
Nature immunology 09, 2019 | Pubmed ID: 31427775
Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues.
Frontiers in microbiology , 2019 | Pubmed ID: 31497010
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.
Journal of virus eradication Sep, 2019 | Pubmed ID: 31700655
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.
Journal of virus eradication Sep, 2019 | Pubmed ID: 31700656